A review on the advances and challenges of immunotherapy for head and neck cancer

Cheng, Gang; Dong, Hui; Yang, Chen; Yang, Liu; Wu, Yi; Zhu, Lifen; Tong, Xiangmin; Wang, Shibing

doi:10.1186/s12935-021-02024-5

Cited by 37 publications

(47 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other PD-1 antibodies, pembrolizumab (Keytruda ® , MSD (Merk Sharp and Duhme) & Co., Inc., Rahway, NJ, USA), and nivolumab (OPDIVO, Bristol-Myers Squibb Co., New York, NY, USA), were recommended in 2020 by the FDA to treat patients with recurrent or metastatic HNSCCs and esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy, respectively [ 100 , 101 ] ( Table 2 ). Other checkpoint inhibitors, such as, Erlotinib and Ipilimumab, that might have beneficial effects with advanced SCC patients are under consideration [ 102 , 103 , 104 , 105 ].…”

Section: Available Treatments For Sccmentioning

confidence: 99%

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges

Ansary

Hossain

Komine

et al. 2022

IJMS

View full text Add to dashboard Cite

Melanoma and nonmelanoma skin cancers (NMSCs) are recognized as among the most common neoplasms, mostly in white people, with an increasing incidence rate. Among the NMSCs, squamous cell carcinoma (SCC) is the most prevalent malignancy known to affect people with a fair complexion who are exposed to extreme ultraviolet radiation (UVR), have a hereditary predisposition, or are immunosuppressed. There are several extrinsic and intrinsic determinants that contribute to the pathophysiology of the SCC. The therapeutic modalities depend on the SCC stages, from actinic keratosis to late-stage multiple metastases. Standard treatments include surgical excision, radiotherapy, and chemotherapy. As SCC represents a favorable tumor microenvironment with high tumor mutational burden, infiltration of immune cells, and expression of immune checkpoints, the SCC tumors are highly responsive to immunotherapies. Until now, there are three checkpoint inhibitors, cemiplimab, pembrolizumab, and nivolumab, that are approved for the treatment of advanced, recurrent, or metastatic SCC patients in the United States. Immunotherapy possesses significant therapeutic benefits for patients with metastatic or locally advanced tumors not eligible for surgery or radiotherapy to avoid the potential toxicity caused by the chemotherapies. Despite the high tolerability and efficiency, the existence of some challenges has been revealed such as, resistance to immunotherapy, less availability of the biomarkers, and difficulty in appropriate patient selection. This review aims to accumulate evidence regarding the genetic alterations related to SCC, the factors that contribute to the potential benefits of immunotherapy, and the challenges to follow this treatment regime.

show abstract

Section: Available Treatments For Sccmentioning

confidence: 99%

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges

Ansary

Hossain

Komine

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Head and neck cancer (HNC) is the 6th most common neoplasm worldwide, with a higher incidence in developing countries [ 1 , 2 ]. In total, 90% of the HNC cases are head and neck squamous cell carcinomas (HNSCC) [ 3 , 4 ]. HNSCC derives from the squamous epithelium of the upper air-digestive tract, affecting different anatomical areas, such as the oral cavity, oropharynx, larynx, and hypopharynx [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy in Head and Neck Cancer When, How, and Why?

Pereira¹,

Martins

Mendes

2022

Biomedicines

View full text Add to dashboard Cite

Head and neck cancer (HNC) is one of the most common cancers worldwide. Alcohol and tobacco consumption, besides viral infections, are the main risk factors associated with this cancer. When diagnosed in advanced stages, HNC patients present a higher probability of recurrence or metastasising. The complexity of therapeutic options and post-treatment surveillance is associated with poor prognosis and reduced overall survival (OS). This review aims to explore immunotherapy (immune checkpoint inhibitors (ICI), therapeutic vaccines, and oncolytic viruses) in HNC patients’ treatment, and to explore when, how, and why patients can benefit from it. The monotherapy with ICI or in combination with chemotherapy (QT) shows the most promising results. Compared to standard therapy, ICI are able to increase OS and patients’ quality of life. QT in combination with ICI demonstrates significant response rates and considerable long-term clinical benefits. However, the toxicity associated with this approach is still a hurdle to overcome. In parallel, the therapeutic vaccines directed to the Human Papilloma Virus are also efficient in increasing the antitumour response, inducing cellular and humoral immunity. Although these results demonstrate clinical benefits compared to standard therapy, it is also important to unravel the resistance mechanisms in order to predict the clinical benefit of immunotherapy.

show abstract

“…By now cancer treatment technology has been greatly improved. The progress of medical technology, especially the combination of different therapies, has improved the survival status of cancer patients [3,4]. Immunotherapy, a revolutionary method of tumor therapy, has been applied in the clinical treatment of a variety of tumors [5].…”

Section: Introductionmentioning

confidence: 99%

Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma

Shen

et al. 2022

Aging

View full text Add to dashboard Cite

Nucleoporin 37 kDa (NUP37), a member of the nucleoporin family, has been reported to regulate the proliferation and apoptosis of several tumor types. However, its role in the tumor immune microenvironment is unclear. Here, we evaluated the expression, methylation, copy number alteration, and prognostic significance of NUP37 using RNA-seq and clinical data from The Cancer Genome Atlas. We observed higher expression of NUP37 in 28 of 29 tumor types, and high NUP37 expression predicted worse survival status of patients in 15 tumors. Using data from the cBioportal database, we described the gene variation of NUP37 in glioma and pancancer. We further assessed the role of NUP37 in the tumor immune microenvironment using immune infiltration data. NUP37 expression was positively associated with the infiltration levels of immunosuppressive cells, such as nTregs, iTregs, and tumor-associated macrophages, and negatively correlated with immune killer cells, such as CD8+ T and NK cells across cancers. Furthermore, NUP37 expression was associated with immune checkpoints and immune regulation-related genes. The half-maximal inhibitory concentrations of anti-cancer drugs were obtained from the Genomics of Drug Sensitivity in the Cancer database. The correlation between half-maximal inhibitory concentration and NUP37 expression was evaluated. The patients with the evaluated expression of NUP37 were resistant to several anti-cancer drugs. These results suggest that NUP37 is a potential oncogene and prognostic biomarker in glioma and pan-cancer. Tumor tissues with high NUP37 expression exist in a relatively immunosuppressive microenvironment and are resistant to several anti-cancer drugs.

show abstract

A review on the advances and challenges of immunotherapy for head and neck cancer

Cited by 37 publications

References 171 publications

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges

Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges

Immunotherapy in Head and Neck Cancer When, How, and Why?

Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma

Contact Info

Product

Resources

About